| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
American Journal of Pathology, Vol 151, 831-841, Copyright © 1997 by American Society for Investigative Pathology
REGULAR ARTICLES |
DJ Abraham, R Vancheeswaran, MR Dashwood, VS Rajkumar, P Pantelides, SW Xu, RM du Bois and CM Black
Academic Unit of Rheumatology and Connective Tissue Diseases, Royal Free Hospital School of Medicine, London, UK.
In addition to their vasoactive action, endothelins are potent peptides in the regulation of both cell proliferation and the turnover of extracellular matrix. Using immunohistochemical, autoradiographic, and molecular analyses, we have studied the localization and expression of endothelin-1 and endothelin A (ETA) and B (ETB) receptors in scleroderma-associated fibrotic lung disease. Increased ET-1 immunoreactivity was found in sclerotic tissue compared with control and was associated with the vasculature, pulmonary interstitium, and bronchial and alveolar epithelium. Microautoradiographic analysis after 125I-labeled ET-1 binding showed a two- to threefold increase in the expression of total ET-1 receptors in scleroderma lung tissue localized to the alveolar epithelium and the pulmonary interstitium which was composed of mainly fibroblastic cells with macrophages and some microvessels. RNAse protection assay revealed significantly reduced ETA receptor and slightly raised ETB message levels in systemic sclerosis lung. Surface expression of functional ET receptors was examined by targeted receptor blocking using mixed and receptor-subtype-selective ligands. A consistent decrease in ETA receptor binding sites was noted primarily within the interstitium and vasculature, in contrast to a slight increase in ETB receptors. Elevated ET-1 and the cell-specific pattern of endothelin receptor expression suggest that the endothelins may represent important mediators that influence the pathology of scleroderma-associated lung disease and other fibrotic conditions.
This article has been cited by other articles:
 |
|
 |
|
  C. F. Opitz, R. Ewert, W. Kirch, and D. Pittrow Inhibition of endothelin receptors in the treatment of pulmonary arterial hypertension: does selectivity matter? Eur. Heart J., June 17, 2008; (2008) ehn234v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Jain, P. W. Shaul, Z. Borok, and B. C. Willis Endothelin-1 Induces Alveolar Epithelial-Mesenchymal Transition through Endothelin Type A Receptor-Mediated Production of TGF-beta1 Am. J. Respir. Cell Mol. Biol., July 1, 2007; 37(1): 38 - 47. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Shi-Wen, F. Rodriguez-Pascual, S. Lamas, A. Holmes, S. Howat, J. D. Pearson, M. R. Dashwood, R. M. du Bois, C. P. Denton, C. M. Black, et al. Constitutive ALK5-Independent c-Jun N-Terminal Kinase Activation Contributes to Endothelin-1 Overexpression in Pulmonary Fibrosis: Evidence of an Autocrine Endothelin Loop Operating through the Endothelin A and B Receptors. Mol. Cell. Biol., July 1, 2006; 26(14): 5518 - 5527. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M H Williams, C Das, C E Handler, M R Akram, J Davar, C P Denton, C J Smith, C M Black, and J G Coghlan Systemic sclerosis associated pulmonary hypertension: improved survival in the current era Heart, July 1, 2006; 92(7): 926 - 932. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Shi-Wen, Y. Chen, C. P. Denton, M. Eastwood, E. A. Renzoni, G. Bou-Gharios, J. D. Pearson, M. Dashwood, R. M. du Bois, C. M. Black, et al. Endothelin-1 Promotes Myofibroblast Induction through the ETA Receptor via a rac/Phosphoinositide 3-Kinase/Akt-dependent Pathway and Is Essential for the Enhanced Contractile Phenotype of Fibrotic Fibroblasts Mol. Biol. Cell, June 1, 2004; 15(6): 2707 - 2719. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Shi-wen, S. L. Howat, E. A. Renzoni, A. Holmes, J. D. Pearson, M. R. Dashwood, G. Bou-Gharios, C. P. Denton, R. M. du Bois, C. M. Black, et al. Endothelin-1 Induces Expression of Matrix-associated Genes in Lung Fibroblasts through MEK/ERK J. Biol. Chem., May 28, 2004; 279(22): 23098 - 23103. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Humbert and J. Cabane Successful treatment of systemic sclerosis digital ulcers and pulmonary arterial hypertension with endothelin receptor antagonist bosentan Rheumatology, January 1, 2003; 42(1): 191 - 193. [Full Text] [PDF]
|
|
|
|
|
|
I. G. Luzina, S. P. Atamas, R. Wise, F. M. Wigley, H. Q. Xiao, and B. White Gene Expression in Bronchoalveolar Lavage Cells from Scleroderma Patients Am. J. Respir. Cell Mol. Biol., May 1, 2002; 26(5): 549 - 557. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. H.S. Kim and L. J. Rubin Endothelin in Health and Disease: Endothelin Receptor Antagonists in the Management of Pulmonary Artery Hypertension Journal of Cardiovascular Pharmacology and Therapeutics, March 1, 2002; 7(1): 9 - 19. [Abstract] [PDF]
|
|
|
|
 |
|
 A. W Barolet, S. Babaei, R. Robinson, P. Picard, W. Tsui, N. Nili, F. Mohamed, O. Ornatsky, J. D Sparkes, D. J Stewart, et al. Administration of exogenous endothelin-1 following vascular balloon injury: early and late effects on intimal hyperplasia Cardiovasc Res, December 1, 2001; 52(3): 468 - 476. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Hocher, A. Schwarz, K. A. Fagan, C. Thöne-Reineke, K. El-Hag, H. Kusserow, S. Elitok, C. Bauer, H.-H. Neumayer, D. M. Rodman, et al. Pulmonary Fibrosis and Chronic Lung Inflammation in ET-1 Transgenic Mice Am. J. Respir. Cell Mol. Biol., July 1, 2000; 23(1): 19 - 26. [Abstract] [Full Text]
|
|
|
|
 |
|
 S. MORGERA, S. KUCHINKE, K. BUDDE, A. LUN, B. HOCHER, and H.-H. NEUMAYER Volume Stress-Induced Peritoneal Endothelin-1 Release in Continuous Ambulatory Peritoneal Dialysis J. Am. Soc. Nephrol., December 1, 1999; 10(12): 2585 - 2590. [Abstract] [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
